File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin

TitleInactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin
Authors
KeywordsAntibodies
Antibody-Dependent Enhancement
COVID-19
COVID-19 Vaccines
Original Antigenic Sin
SARS-CoV-2 Variants
Issue Date23-May-2023
PublisherElsevier
Citation
Immunology Letters, 2023, v. 259, p. 21-23 How to Cite?
Abstract

Inactivated vaccine is one of the platforms employed in COVID-19 vaccines. Inactivated vaccines have been associated with concerns of antibody-dependent enhancement (ADE) and original antigenic sin (OAS), which are related to non-neutralising or poorly neutralising antibodies against the pathogen. Since inactivated COVID-19 vaccines use whole-SARS-CoV-2 virus as the immunogen, they are expected to generate antibodies against non-spike structural proteins, which are highly conservative across variants of SARS-CoV-2. These antibodies against non-spike structural proteins have found to be largely non-neutralising or poorly neutralising in nature. Hence, inactivated COVID-19 vaccines could possibly be associated with ADE and OAS, especially as novel variants emerge. This article explores the potential concern of ADE and OAS in the context of inactivated COVID-19 vaccine, and outlines the future research directions.


Persistent Identifierhttp://hdl.handle.net/10722/331467
ISSN
2023 Impact Factor: 3.3
2023 SCImago Journal Rankings: 1.020
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKan, Andy Ka Chun-
dc.contributor.authorLi, Philip Hei-
dc.date.accessioned2023-09-21T06:56:00Z-
dc.date.available2023-09-21T06:56:00Z-
dc.date.issued2023-05-23-
dc.identifier.citationImmunology Letters, 2023, v. 259, p. 21-23-
dc.identifier.issn0165-2478-
dc.identifier.urihttp://hdl.handle.net/10722/331467-
dc.description.abstract<p> Inactivated vaccine is one of the platforms employed in COVID-19 vaccines. Inactivated vaccines have been associated with concerns of antibody-dependent enhancement (ADE) and original antigenic sin (OAS), which are related to non-neutralising or poorly neutralising antibodies against the pathogen. Since inactivated COVID-19 vaccines use whole-SARS-CoV-2 virus as the immunogen, they are expected to generate antibodies against non-spike structural proteins, which are highly conservative across variants of SARS-CoV-2. These antibodies against non-spike structural proteins have found to be largely non-neutralising or poorly neutralising in nature. Hence, inactivated COVID-19 vaccines could possibly be associated with ADE and OAS, especially as novel variants emerge. This article explores the potential concern of ADE and OAS in the context of inactivated COVID-19 vaccine, and outlines the future research directions. <br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofImmunology Letters-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAntibodies-
dc.subjectAntibody-Dependent Enhancement-
dc.subjectCOVID-19-
dc.subjectCOVID-19 Vaccines-
dc.subjectOriginal Antigenic Sin-
dc.subjectSARS-CoV-2 Variants-
dc.titleInactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin-
dc.typeArticle-
dc.identifier.doi10.1016/j.imlet.2023.05.007-
dc.identifier.scopuseid_2-s2.0-85162773488-
dc.identifier.volume259-
dc.identifier.spage21-
dc.identifier.epage23-
dc.identifier.isiWOS:001008167000001-
dc.identifier.issnl0165-2478-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats